Taken together, in the present study we demonstrated that W2014-S, as a novel STAT3 inhibitor, effectively inhibited STAT3 signaling with potent anti-tumor activities in human lung cancer, and enhanced the sensitivity of resistant NSCLC to gefitinib in vitro and in vivo. The gene discussed is STAT3; the disease is lung cancer.